CYSLTR2 and Parkinson disease: This action was inhibited by montelukast via the CysLTR1-mediated p38 MAPK/NF-κB pathway [82,107,111], and also by selective inhibition or knockout of CysLTR2 [86], suggesting that CysLTR1 and CysLTR2 could be strategic targets against PD.